- Home
- FMST vs EDSA Comparison
FMST vs EDSA Comparison
Compare FMST & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | EDSA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 12.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FMST | EDSA |
|---|---|---|
| Price | $2.54 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 315.7K | 32.3K |
| Earning Date | 11-13-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.44 |
| 52 Week High | $5.74 | $4.49 |
Technical Indicators
Market Signals| Indicator | FMST | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 31.23 |
| Support Level | $2.64 | $1.44 |
| Resistance Level | $3.49 | $1.54 |
| Average True Range (ATR) | 0.28 | 0.08 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 3.03 | 10.53 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.